Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-10-27 Governance Information
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 投资者关系管理制度' which translates to 'Investor Relations Management System' of the company. It details the company's policies, principles, responsibilities, and procedures for managing investor relations, including communication with investors, disclosure principles, and internal controls. It is a governance-related document outlining internal rules and practices rather than a financial report, earnings release, or announcement of voting results. It is not a report publication announcement since it contains substantive content rather than a brief notice. The document does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, capital update, or legal proceeding report. The content fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. Confidence is high given the detailed governance content and absence of financial data or other report types.
2022-10-27 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 对外担保管理制度' which translates to 'Yunnan Biological Valley Pharmaceutical Co., Ltd. External Guarantee Management System'. It details the company's internal policy and procedures regarding external guarantees, including approval processes, risk management, contract requirements, disclosure obligations, and legal responsibilities. The document references board and shareholder meetings for approval but does not present financial statements or results. It is a governance-related internal policy document rather than a financial report or announcement. It is not a report publication announcement since it contains substantive content and is over 5,000 characters. It fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to external guarantees.
2022-10-27 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 对外投资管理制度' which translates to 'Yunnan Biological Valley Pharmaceutical Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the company's procedures, principles, and organizational structure for managing external investments. It includes sections on approval authority, organizational management, decision-making, financial management, personnel management, transfer and recovery of investments, and information disclosure obligations. The document is dated October 28, 2022, and is issued by the company's board of directors. There is no indication that this is a financial report, earnings release, or regulatory filing. It is not an announcement of a report but a governance or management policy document. Given the content focuses on internal rules and governance practices related to investment management, the most appropriate classification is Governance Information (CGR).
2022-10-27 Chinese
关于对外投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external investment to establish a wholly-owned subsidiary. It includes details about the investment amount, purpose, board approval, and regulatory compliance. There are no financial statements or detailed financial performance data. The document is a formal announcement of a capital investment activity, specifically the establishment of a new subsidiary, which relates to capital structure changes but does not constitute a major asset restructuring or merger. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2022-10-27 Chinese
关于召开2022年第四次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2022 fourth extraordinary general meeting of shareholders (临时股东大会) for Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendees, agenda items, registration procedures, and contact information. It does not contain financial statements, audit results, or detailed management discussion. It is not a report itself but an announcement about a shareholders meeting. The content aligns with a notice for a shareholder meeting rather than the meeting materials or voting results. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not the solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is 2603 characters, which is short and typical for a meeting notice. Hence, the classification is RNS with high confidence.
2022-10-27 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the company's internal policies and procedures for managing raised funds. It includes sections on storage, usage, supervision, and changes in the use of raised capital. The document references regulatory requirements and internal governance but does not present financial statements or results. It is a detailed policy document related to capital management rather than a financial report or announcement of a report. It is not a brief announcement or a certification letter but a substantive internal governance document. Therefore, it fits best under 'Capital/Financing Update' (CAP) as it provides an update on the company's fundraising capital management rules and procedures.
2022-10-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.